Early-feasibility Study to Evaluate Usability and Safety of the Watch-Transcutaneous Electrical Acustimulation (TEA) Device

Not Applicable

Not yet recruiting

• Conditions: Healthy
• Interventions: Device: Watch-TEA group; Device: Tethered TEA device

• Registration Number: NCT06366074
• Lead Sponsor: University of Michigan

Brief Summary

This project is being completed to test the usability and safety of the Watch-Transcutaneous Electrical Acustimulation (TEA) Device.

This is a pilot study that will lead to future projects for cancer patients that may experience chemotherapy-induced symptoms.

Detailed Description

This project will include three different aims (aim three is a clinical trial) and will be funded by the National Institute of Health (NIH). In aims 1 and 2 the device hardware and device application will be developed and will not be included in this registration as these are not clinical trials. However, aim three is being registered early in the project in order to obtain the Notice of Award (NOA) funding from the NIH. Once the NOA has been obtained the registration will be updated.

Study Timeline

• Study First Submitted: 2024-04-01
• Study First Submitted QC: 2024-04-09
• Study First Posted: 2024-04-15
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-04
• Last Update Posted: 2024-10-08
• Study Start: 2025-10
• Primary Completion: 2026-10
• Study Completion: 2026-10

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Participants that are willing and able to come to the clinic for two scheduled visits
• Participants are capable of understanding clinical study procedures
• Participants agree to complete the questionnaires

Exclusion Criteria

• Participants with implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)
• Those enrolled in a concurrent clinical study
• Those unable to comply with the study protocol due to a disease, psychiatric illness, alcoholism, substance abuse, geographic distance, or other factors that would place the study participant at increased risk or preclude the study participant's full compliance with or completion of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Watch-TEA	Watch-TEA group	-
Watch-TEA	Tethered TEA device	-
Tethered TEA device	Watch-TEA group	-
Tethered TEA device	Tethered TEA device	-

Primary Outcome Measures

Name	Time	Method
Usability of the device for both groups day 3	Day 3	Questionnaires are administered online and there are 17 usability questions in the questionnaire. All answers use 0-to-5 scale (0 - no,1 - minor, 2 - some, 3 - considerable, 4 - major, 5 - critical) with a range of 0-85 with a higher score meaning more usable.
Number of TEA-related adverse events for both groups 60 minutes at maximal tolerable level	Daily for 3 days	The subjects will self-apply the TEA for 60 minutes once daily with the current amplitude set at a maximal tolerable level. Events collected will include skin irritation, pain, or infection.; Adverse events will be noted by the following: 1. - Mild AE - No treatment needed; 2. - Moderate AE - Resolved with treatment; 3. - Severe AE - Inability to carry on normal activities, required professional medical attention; 4. - Life-threatening or disabling AE; 5. - Fatal AE
Number of non-treatment TEA adverse events for both groups	up to 1-2 weeks (after baseline visit 1)	Adverse events will be noted by the following: 1. - Mild AE - No treatment needed; 2. - Moderate AE - Resolved with treatment; 3. - Severe AE - Inability to carry on normal activities, required professional medical attention; 4. - Life-threatening or disabling AE; 5. - Fatal AE
Number of Transcutaneous Electrical Acustimulation (TEA)-related adverse events for both groups 3 days	Day 3	These will include skin irritation, pain, or infection under the Watch-TEA and tethered TEA devices after wearing each device for 3 consecutive days.; Adverse events will be noted by the following: 1. - Mild averse event (AE) - No treatment needed; 2. - Moderate AE - Resolved with treatment; 3. - Severe AE - Inability to carry on normal activities, required professional medical attention; 4. - Life-threatening or disabling AE; 5. - Fatal AE
Number of adverse events related to the device noted on the safety questionnaire	1-2 weeks (after baseline visit 1)	A safety questionnaire with 3 questions about skin irritation, pain, or infection. Visit 2 is at 1-2 weeks after visit 1.

Trial Locations

Locations (1)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States